The Pan American Health Organization (PAHO) last week announced a new pathway to access lenacapavir for HIV prevention in Latin America and the Caribbean through its Regional Revolving Funds, under an agreement with Gilead Sciences. The initiative will make the long-acting HIV prevention medicine available to 14 countries, complementing existing access mechanisms and supporting efforts to expand HIV prevention options across the Region.
Approximately 140,000 new HIV infections occur each year in Latin America and the Caribbean, underscoring the need to expand access to effective and acceptable prevention options.
